MANHATTAN BEACH, Calif., Nov. 10, 2010 /PRNewswire-FirstCall/ -- Genesis Biopharma, Inc. (OTC Bulletin Board: GNBP), a biotechnology company developing targeted cancer therapies, has formed Genesis Advanced Development Programs (Genesis ADP) to initiate and promote drug development collaborations with leading academic researchers. An initial focus of Genesis ADP will be screening libraries of approved drugs for their use in low-cost development of cocktail drug therapies.
"The objective of Genesis ADP is to transform revolutionary academic science into pragmatic drug development programs," said Robert Brooke, Genesis Biopharma president and CEO. "We are seeking effective cocktail therapies and plan to pursue the cost- and time-effective 505(b)(2) regulatory pathway for U.S. market approval.
"Our primary focus at Genesis is on developing and partnering our anti-CD55 monoclonal antibody program, which targets a key cancer defense mechanism that is over-expressed in more than 80% of solid tumors," he added. "That said, each Genesis ADP collaboration will have significant potential and could become an important part of our development efforts in future years."
Genesis ADP Scientific Advisory Board
Genesis also announced the formation of the Genesis ADP Scientific Advisory Board comprised of the following members:
- Aubrey de Grey, Ph.D., is a biomedical gerontologist based in Cambridge, UK. He serves as Chief Scientific Officer of the SENS Foundation, an organization working to develop, promote and ensure widespread access to rejuvenation biotechnologies that comprehensively address the disabilities and diseases of aging. He is developer of the SENS regenerative medicine paradigm. Dr. de Grey most recently served as Chairman and Chief Science Officer of the Methuselah Foundation, a non-profit charity dedicated to combating the aging process. He also is the Editor-in-Chief of the peer-reviewed journal Rejuvenation Research.
- L. Stephen Coles, MD, Ph.D., is a recognized expert on aging and supercentenarians. He currently serves as a Visiting Scholar at the UCLA Department of Computer Science. He co-founded the Los Angeles Gerontology Research Group and serves as a Director and Treasurer of the Supercentenarian Research Foundation, which studies persons who have lived to be 110 years or older. Dr. Coles received his B.S. in electrical engineering from Rensselaer Polytechnic Institute, his Master's in mathematics from the Carnegie Institute of Technology, and his Ph.D. in systems and communication sciences from Carnegie-Mellon University.
- Zheng Cui, MD, Ph.D., is a biochemist and currently serves as an Associate Professor of Pathology (Tumor Biology) at Wake Forest University. His research into granulocyte therapy made headlines by achieving a complete cure for all types of cancer tested in mice. As an oncologist and a cancer researcher, he has proposed that certain individuals naturally produce a special kind of white blood cell that contains an inherent resistance to cancer. These white blood cells could potentially be extracted from donors and given to cancer victims, thus endowing them with cancer resistance.
About Genesis Biopharma, Inc.
Genesis Biopharma, Inc. is a development-stage biotechnology company engaged primarily in the development of targeted cancer therapies. For more information on the company, visit www.genesis-biopharma.com.
The foregoing press announcement contains forward-looking statements that can be identified by such terminology as "expect," "potential," "suggests," "bodes," "may," "should," "could" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the company's ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as of the date they are made. The company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.
SOURCE Genesis Biopharma, Inc.